Thyroid Therapy Medicinal Products Market Procurement Intelligence Report

Several macro changes in the dynamics of overall Drugs and Biological as well as Thyroid Therapy Medicinal Products procurement trends are poised to change the business practices and procurement thumb rules. Despite increasing costs on almost all fronts, suppliers are resisting a drastic price increase due to intense competition where market players are willing to increase their market share at the cost of profitability. Therefore, buyers can expect pricing status quo in most cases, or only negligible to marginal price increases in some cases.

New locations and vendors are emerging as cost effective suppliers of Thyroid Therapy Medicinal Products, offering an opportunity to widen the supplier base and gain further negotiation leverage with incumbent suppliers.

Providers are increasing their adoption of new tools and technologies to optimize efficiencies and reduce the time taken to launch products in the market. This is adding to their OPEX and will have an inflationary impact on the overall price paid by the buyers.

Category managers need to take note of the potential of these developments and reassess the changes required in their procurement practices.

Sometimes, procurement functions are unable to timely alter their practices while responding to market conditions. Industry experts acknowledge that periodically reviewing procurement best practices and adopting learnings from across procurement categories can help procurement teams respond to market needs in a more agile way. This report combines our experience of other categories with Thyroid Therapy Medicinal Products procurement insights and hand picks best practices that can work for category managers delving in this market.

For example, Large organizational buyers can leverage their scale of operations to initiate competitive bidding between suppliers. Competitive bidding would enable buyers to have a better visibility of the market prices and may help identify suppliers that offer the most competitive price offering viz-a-viz other players.

Buyers should look to minimize the contract-related risks where unfavorable credit terms may severly penalize buyers for delayed payments or entitle the supplier to demand pre-payments or shorten the payment terms. Although these clauses are not very common in the category, suppliers may still insist on them, especially in situations where buyers' liquidity or financial health is in question.

It is important for category managers to track and measure the performance of suppliers against a set of defined KPIs that are agreed upon during the contract negotiation phase. The performance of suppliers can also be linked to a portion of their fee that can be paid upon rendering of services in a satisfactory manner.

Thyroid Therapy Medicinal Products procurement managers also need to proactively identify and mitigate potential risks that can arise in the supply chain or contracts for Thyroid Therapy Medicinal Products procurement. Some examples include: